Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucoregulatory effects of oxyntomodulin and liraglutide in adults with type 2 diabetes mellitus
NL-OMON35750Phase 2Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- May 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of oxyntomodulin, liraglutide and insulin aspart in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by PRA Health Sciences. Primary endpoints: Glycemic effects of single-dose oxyntomodulin, Insulinotropic effects of single-dose oxyntomodulin and 3 more. Started May 2011; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON35750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35750.